China Medical System Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Kong Lam

Chief executive officer

CN¥5.4m

Total compensation

CEO salary percentage	93.5%
CEO tenure	17.3yrs
CEO ownership	46.6%
Management average tenure	no data
Board average tenure	11.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kong Lam's remuneration changed compared to China Medical System Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	CN¥5m	CN¥5m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥3b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥6m	CN¥5m	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥3b
Dec 31 2021	CN¥5m	CN¥4m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥3b
Dec 31 2020	CN¥4m	CN¥4m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥2b
Mar 31 2020	n/a	n/a	CN¥2b
Dec 31 2019	CN¥4m	CN¥3m	CN¥2b
Sep 30 2019	n/a	n/a	CN¥2b
Jun 30 2019	n/a	n/a	CN¥2b
Mar 31 2019	n/a	n/a	CN¥2b
Dec 31 2018	CN¥3m	CN¥3m	CN¥2b
Sep 30 2018	n/a	n/a	CN¥2b
Jun 30 2018	n/a	n/a	CN¥2b
Mar 31 2018	n/a	n/a	CN¥2b
Dec 31 2017	CN¥782k	CN¥610k	CN¥2b

Compensation vs Market: Kong's total compensation ($USD752.65K) is below average for companies of similar size in the German market ($USD1.62M).

Compensation vs Earnings: Kong's compensation has been consistent with company performance over the past year.

CEO

Kong Lam (58 yo)

17.3yrs

Tenure

CN¥5,443,000

Compensation

Dr. Lam Kong founded and serves as the Chairman and Chief Executive Officer of China Medical System Holdings Limited and has been its Executive Director since December 18, 2006. Mr. Lam serves as President...

Board Members

Name	Position	Tenure	Compensation	Ownership
Kong Lam	Founder	17.3yrs	CN¥5.44m	46.63% CN¥ 978.9m
Yanling Chen	CFO, VP & Executive Director	17.3yrs	CN¥4.43m	0.30% CN¥ 6.2m
Hongbing Chen	COO, VP	17.3yrs	CN¥5.04m	2.88% CN¥ 60.5m
Chong Shun Leung	Independent Non-Executive Director	6.3yrs	CN¥323.00k	no data
Ying Luo	Independent Non-Executive Director	4.1yrs	CN¥323.00k	no data
Ching Fung	Independent Non-Executive Director	2.5yrs	CN¥323.00k	no data

11.8yrs

Average Tenure

57yo

Average Age

Experienced Board: 2M7C's board of directors are seasoned and experienced ( 11.8 years average tenure).

China Medical System Holdings Management

Management criteria checks 3/4

Key information

Recent management updates

China Medical System Holdings Limited, Annual General Meeting, May 09, 2024

Founder recently bought €2.4m worth of stock

Founder recently bought €1.9m worth of stock

Recent updates

China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China

Now 21% undervalued after recent price drop

Final dividend of HK$0.086 announced

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

New major risk - Share price stability

Now 38% undervalued after recent price drop

China Medical System Holdings Limited, Annual General Meeting, May 09, 2024

Full year 2023 earnings released: EPS: CN¥0.98 (vs CN¥1.33 in FY 2022)

China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024

China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China

China Medical System Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China

China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application (Nda) for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China

Upcoming dividend of HK$0.34 per share at 5.1% yield

First half 2023 earnings released: EPS: CN¥0.78 (vs CN¥0.73 in 1H 2022)

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 20, 2023

China Medical System Holdings Limited to Report First Half, 2023 Results on Aug 28, 2023

New minor risk - Share price stability

China Medical System Holdings Limited Receives Approval from National Medical Products Administration of China for New Drug Application of Diazepam Nasal Spray

National Medical Products Administration of China Approves China Medical System Holdings's New Drug Application of Tildrakizumab Injection under the Brand Name of ILUMETRI

Upcoming dividend of HK$0.27 per share at 4.7% yield

Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021)

Full year 2022 earnings released: EPS: CN¥1.33 (vs CN¥1.22 in FY 2021)

China Medical System Holdings Limited Announces New Drug Application of Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets

China Medical System Holdings Limited Announces its Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets Obtains Positive Results for its Phase III Clinical Trial in China

Investor sentiment improved over the past week

Upcoming dividend of HK$0.34 per share

First half 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.66 in 1H 2021)

China Medical System Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 15 September 2022

China Medical System Holdings Limited to Report First Half, 2022 Results on Aug 22, 2022

China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.28 per share

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

China Medical System Holdings Limited to Report Fiscal Year 2021 Results on Mar 15, 2022

China Medical System Holdings Limited Announces New Drug Application of Methotrexate Injection, Pre-Filled Syringe Accepted in China

Independent Non-Executive Director Chi Keung Wu has left the company

China Medical System Holdings Limited Establishes A New Programme with XF-73 Targeting the Prevention and Treatment of Superficial Skin Infections Caused by Bacteria

Upcoming dividend of HK$0.32 per share

First half 2021 earnings released: EPS CN¥0.66 (vs CN¥0.52 in 1H 2020)

National Medical Products Grants Approval to China Medical System Holdings Limited's Methotrexate Injection, Pre-Filled Syringe

China Medical System Holdings Limited Receives Approval for Innovative Patented Drug Methylthioninium Chloride Enteric-Coated Sustained-Release Tablets

Investor sentiment deteriorated over the past week

China Medical System Holdings Limited Announces That the Group's Innovative Drug Tildrakizumab Solution for Injection Obtained Positive Results of Its Phase Clinical Trial in China

Investor sentiment deteriorated over the past week

China Medical System Holdings Limited Announces New Drug Application of Diazepam Nasal Spray Accepted in China

China Medical System Holdings Limited Approves Final Dividend for the Year Ended December 31, 2020

Upcoming dividend of HK$0.24 per share

Full year 2020 earnings released: EPS CN¥1.02 (vs CN¥0.79 in FY 2019)

Full year 2020 earnings released

China Medical System Holdings Limited Recommends a Final Dividend for the Year Ended 31 December 2020, Payable About 10 May 2021

New 90-day high: €1.53

Investor sentiment improved over the past week

China Medical System Holdings Limited to Report Fiscal Year 2020 Results on Mar 16, 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

China Medical System Holdings Limited (SEHK:867) acquired Luqa Ventures Co., Ltd. from third party sellers.

New 90-day high: €1.11

Investor sentiment improved over the past week

China Medical System Holdings Limited Announces Desidustat Tablets Being Granted an Approval for Drug Clinical Trial

Investor sentiment improved over the past week

New 90-day high: €0.98

Founder recently bought €2.4m worth of stock

New 90-day low: €0.76

China Medical System Holdings Limited through its Wholly-Owned Subsidiary Signs License, Collaboration and Distribution Agreement with Cosmo Technologies Ltd

New 90-day low: €0.85

New 90-day low: €0.91

New 90-day low: €0.92

China Medical System Holdings Limited Signs A Distribution, Supply and License Agreement (The "License Agreement"), with medac Gesellschaft für klinische Spezialpräparate mbH

Founder recently bought €1.9m worth of stock

New 90-day low - €0.93

First half earnings released